To determine whether statin-mediated enhancement in ADC-tumor binding is dependent on CAV1 tumoral levels, we performed biodistribution studies with 89Zr-labeled TDM1 in the HER2-positive gastric PDXs shown in Fig. 1a. This evidence concerns the gene CAV1 and neoplasm.